Victoza for People with Type 1 Diabetes? (Continued)
dLife Editor's note —
diaTribe Editor Kelly Close's column received a great response from her readers and she reprinted the column in November 2010 with the following additional information:
Someone asked me how I use Symlin in my diabetes regimen that includes a daily shot of Victoza. While initially I stopped using Symlin for a little while, I'm now using it again, with insulin and Victoza — not before every meal, but definitely before all my high-carb meals. My sense is that as a patient with diabetes, I am probably missing multiple important hormones. Symlin works very well for me in lowering my post-meal blood glucose levels and when I'm eating pizza or a sandwich or fettucini, I still take Symlin to reduce these numbers — and it does. I am eager to eventually try an insulin/Symlin combo, since I have heard from so many people that Symlin works best in a pump — here's hoping that will be developed soon. (I tried Symlin in an extra pump myself and loved it and only quit because my insurance didn't reimburse the extra pods — I'd rather wear one pump and have the combined insulin/Symlin to take, if this could be created in a formulation that worked for many people.)
Novo Nordisk then issued their own response:
We read the diaTribe article describing your recent experience using Victoza as an adjunct to insulin to treat your type 1 diabetes. We are happy to hear that Victoza has lowered your mean glucose levels and also has resulted in a decrease in the frequency of both high and low glucose levels.
Our development program established a strong foundation for the use of Victoza as monotherapy or in combination with one or two oral agents in type 2 diabetes. As you pointed out, Victoza has not yet been studied in or approved for the treatment of type 1 diabetes, and it is not a substitute for insulin. However, your personal experience provides one of many reasons why Novo Nordisk is currently considering exploring the use of Victoza for type 1 diabetes in well-designed, controlled, randomized clinical trials. While we can not guarantee the time course or the outcome, we are carefully evaluating the possibilities for launching such a program.
Thank you for making us aware of your experience and for sharing so many insights about living with diabetes.
Alan C. Moses, MD, FACP
Global Chief Medical Officer
Novo Nordisk A/S
Mads Krosgard Thomsen
Chief Scientific Officer
Novo Nordisk A/S
diaTribe is an independent, advertising-free e-newsletter for everyone eager to learn about the latest advances in diabetes management. diaTribe is your inside track on diabetes research and products — sign up here for your complimentary lifetime subscription!
NOTE: This information is not intended to be a replacement or substitute for consultation with a qualified medical professional or for professional advice related to diabetes or another medical condition. Please contact your physician or medical professional with any questions and concerns about your medical condition.
Surveys Find Adults with Type 2 Diabetes Are More Willing to Take Action to Achieve A1C Targets Quicker than Physicians and Other Medical Professionals Perceive
FDA Votes to Change Jardiance Label to Show Reduction in Heart-Related Deaths
Low Carb vs. High Carb II – My Diabetes Diet Battle Continued
Easy Pear Crisp Mushroom-Spinach Stuffed Beef Tenderloin Seasoned Garlicky Meatballs Tuna, Mushrooms, and Celery Vanilla Maple Cream Chicken in Plum Salsa Hash Brown Casserole Bacon & Boursin Cheese Puff Pastry Chocolate-Caramel Treats Seafood in a Tomato Stew
Years before I was diagnosed with type 2 diabetes, The Other Half came out of a doctor's appointment with a diagnosis of "borderline diabetes" and an ADA exchange diet sheet. His health insurance agency followed up on the diagnosis with a glucometer and test strips. After a year or so of trying to follow the diet plan and test his glucose levels, things appeared to be back in "normal" range, and stood there until a couple of years after my own diagnosis. Shortly...